CXCL8 and gastric cancer: Remarkably in gastric cancer, artemisinins reverse the IκBα level, prevent NF-κB pathway in a dose-dependent manner, and decrease the generation of downstream inflammatory factors such as TNF-α (tumor necrosis factor-α) and IL-8 (interleukin-8) (Su et al., 2019).